Skip to main content

Lab-grown snake venom glands are here. Don’t worry, they’re for a good cause

Snake Venom Gland Organoids

Every year, the equivalent of the total population of Tuscaloosa, Alabama — slightly more than 100,000 people — die worldwide as a result of snake bites. Provided a snake bite victim is able to get to the emergency room quick enough, antivenom can be used to counter the deadly effects of a bite. But antivenom isn’t easy to manufacture. It’s made by collecting venom from venomous snakes and injecting small quantities of it into a domestic animal such as a horse. The antibodies that form can then be collected from the horse’s blood and purified to make a finished antivenom. So far, so straightforward.

The problem is getting hold of enough venom to make it. Antivenom is currently manufactured by catching or breeding snakes, keeping them in captivity, and then regularly “milking” them to gather the venom they produce. It’s a 19th century treatment that’s made necessary by the fact that antivenom production has not developed as fast as other areas of biotechnology. With 600 species of venomous snake, it’s also a labour-intensive job which nonetheless struggles to create antidotes enough to meet the number of annual snake bites. Could genetic engineering be the answer?

Brightfield images of organoids in culture (Aspidelaps lubricus)
Brightfield image of organoids in culture (Aspidelaps lubricus) Joep Beumer, Jens Puschhof, Yorick post, Hubrecht Institute

A group of three researchers at Utrecht University in the Netherlands think so. And their idea for achieving it is kind of brilliant. Rather than creating lab-grown venomous snakes — an idea that, frankly, would only sound good to one of the screenwriters of Sharknado — they’ve come up with an alternative solution: Simply grow the part of the snake that you need.

Experiments in cold blood

“We were thinking about novel areas for [our] organoid technology,” Hans Clevers, whose lab carried out the work, told Digital Trends. “Snake venom glands were the most fascinating tissue to us. A main first hurdle was to obtain snake tissue. Luckily, a collaboration with snake experts Michael Richardson and Freek Vonk, as well as the Dutch reptile zoo ‘Serpo’ and local breeders solved this issue. After some months of optimizing the protocols, we were successful in growing miniature venom glands. Since then, we have been optimizing the protocol to produce venom and have characterized the cells which make the toxins.”

Aspidelaps lubricus hatching (individuals not used in study) Jeremie Tai-A-Pin

An organoid, for those unfamiliar with it, is a miniaturized and simplified version of an organ, complete with realistic micro-anatomy. They’re made using stem cells, which let them self-organize in a three-dimensional culture to transform into the organ they’re supposed to replicate. The emerging organ is a clump of cells around 1 millimeter across. Organoids have been created by various labs around the world, approximating organs that range from kidneys to miniature, non-conscious brains. In this case, the venomous organoids resemble a tiny pea-sized balloon filled with liquid. One that would be particularly inhumane to fire across the classroom like a spitball wad.

“Our group has been successful in the past 10 years in growing organoids from a variety of human tissues,” Joep Beumer, another researcher on the project, explained. “To generate these, we harvest stem cells from adult tissue and embed them into a gel in a petri dish. With the right growth factor mix, the stem cells will divide and give rise to mini-organs containing the different cell types of one tissue.”

Immunofluorescent images of Aspidelaps lubricus organoids
Immunofluorescent image of Aspidelaps lubricus organoids Ravian van Ineveld, Princess Maxima Center

The tissue samples for the venom organoids were taken from gland tissue from snake embryos inside eggs or, in one instance, from a pet snake which had been put down as a result of illness. To grow the gland organoids, the team had to make a few changes to their normal approach. Snakes are cold-blooded. Mammalian organoid protocols are normally grown at a temperature of 37 degrees Celsius (99 degrees Fahrenheit). Unfortunately, this didn’t work for the snake organoids. At this temperature, the organoids suffered heat shock response and died. As a result, they had to lower the temperature to 32 degrees Celsius. It’s a demonstration of how, even at this scale, the concepts and signaling pathways of adult stem cells are conserved in organoids.

Scaling it up

“Every tissue has its own characteristics which we aim to model with organoids,” said Yorick Post, the third researcher on the project. “For the snake venom gland this was a very obvious case: would they make venom? We knew that the potential of this technology would hinge greatly on the ability to produce the different toxins which constitute snake venom. So we were very excited when we found toxins — first on RNA, and later on [the] protein level.”

This work is extremely promising. The researchers think it could potentially go beyond just cutting out the snake-farming part of the antivenom process as well. They believe it might be possible to grow the immune cells that are usually produced by animals inside a dish. Alongside antivenom, the approach could also be useful for helping develop drug compounds based on components found in snake venom. For instance, there’s a certain type of blood pressure medicine that’s created from a toxin produced by the venomous Brazilian pit viper.

Naja atra eggs
Naja atra eggs Joep Beumer, Jens Puschhof, Yorick post, Hubrecht Institute

And as to, no pun intended, the scaling up part of the project? “This is one of the main advantages of organoid technology,” Clevers said. “Once established, we can expand the tissue [in a] pretty much unlimited [manner]. This can help to preserve viable cells of many snake species, as they can be frozen and thawed easily. [It can also help us] generate large numbers of venom producing cells. Further improvements in venom production and harvesting will be needed to make this approach cost efficient. We are actively working towards these aims.”

A paper describing the work was recently published in the journal Cell.

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Star Wars legend Ian McDiarmid gets questions about the Emperor’s sex life
Ian McDiarmid as the Emperor in Star Wars: The Rise of Skywalker.

This weekend, the Star Wars: Revenge of the Sith 20th anniversary re-release had a much stronger performance than expected with $25 million and a second-place finish behind Sinners. Revenge of the Sith was the culmination of plans by Chancellor Palpatine (Ian McDiarmid) that led to the fall of the Jedi and his own ascension to emperor. Because McDiarmid's Emperor died in his first appearance -- 1983's Return of the Jedi -- Revenge of the Sith was supposed to be his live-action swan song. However, Palpatine's return in Star Wars: Episode IX -- The Rise of Skywalker left McDiarmid being asked questions about his character's comeback, particularly about his sex life and how he could have a granddaughter.

While speaking with Variety, McDiarmid noted that fans have asked him "slightly embarrassing questions" about Palpatine including "'Does this evil monster ever have sex?'"

Read more
Waymo and Toyota explore personally owned self-driving cars
Front three quarter view of the 2023 Toyota bZ4X.

Waymo and Toyota have announced they’re exploring a strategic collaboration—and one of the most exciting possibilities on the table is bringing fully-automated driving technology to personally owned vehicles.
Alphabet-owned Waymo has made its name with its robotaxi service, the only one currently operating in the U.S. Its vehicles, including Jaguars and Hyundai Ioniq 5s, have logged tens of millions of autonomous miles on the streets of San Francisco, Los Angeles, Phoenix, and Austin.
But shifting to personally owned self-driving cars is a much more complex challenge.
While safety regulations are expected to loosen under the Trump administration, the National Highway Traffic Safety Administration (NHTSA) has so far taken a cautious approach to the deployment of fully autonomous vehicles. General Motors-backed Cruise robotaxi was forced to suspend operations in 2023 following a fatal collision.
While the partnership with Toyota is still in the early stages, Waymo says it will initially study how to merge its autonomous systems with the Japanese automaker’s consumer vehicle platforms.
In a recent call with analysts, Alphabet CEO Sundar Pichai signaled that Waymo is seriously considering expanding beyond ride-hailing fleets and into personal ownership. While nothing is confirmed, the partnership with Toyota adds credibility—and manufacturing muscle—to that vision.
Toyota brings decades of safety innovation to the table, including its widely adopted Toyota Safety Sense technology. Through its software division, Woven by Toyota, the company is also pushing into next-generation vehicle platforms. With Waymo, Toyota is now also looking at how automation can evolve beyond assisted driving and into full autonomy for individual drivers.
This move also turns up the heat on Tesla, which has long promised fully self-driving vehicles for consumers. While Tesla continues to refine its Full Self-Driving (FSD) software, it remains supervised and hasn’t yet delivered on full autonomy. CEO Elon Musk is promising to launch some of its first robotaxis in Austin in June.
When it comes to self-driving cars, Waymo and Tesla are taking very different roads. Tesla aims to deliver affordability and scale with its camera, AI-based software. Waymo, by contrast, uses a more expensive technology relying on pre-mapped roads, sensors, cameras, radar and lidar (a laser-light radar), that regulators have been quicker to trust.

Read more
Uber partners with May Mobility to bring thousands of autonomous vehicles to U.S. streets
uber may mobility av rides partnership

The self-driving race is shifting into high gear, and Uber just added more horsepower. In a new multi-year partnership, Uber and autonomous vehicle (AV) company May Mobility will begin rolling out driverless rides in Arlington, Texas by the end of 2025—with thousands more vehicles planned across the U.S. in the coming years.
Uber has already taken serious steps towards making autonomous ride-hailing a mainstream option. The company already works with Waymo, whose robotaxis are live in multiple cities, and now it’s welcoming May Mobility’s hybrid-electric Toyota Sienna vans to its platform. The vehicles will launch with safety drivers at first but are expected to go fully autonomous as deployments mature.
May Mobility isn’t new to this game. Backed by Toyota, BMW, and other major players, it’s been running AV services in geofenced areas since 2021. Its AI-powered Multi-Policy Decision Making (MPDM) tech allows it to react quickly and safely to unpredictable real-world conditions—something that’s helped it earn trust in city partnerships across the U.S. and Japan.
This expansion into ride-hailing is part of a broader industry trend. Waymo, widely seen as the current AV frontrunner, continues scaling its service in cities like Phoenix and Austin. Tesla, meanwhile, is preparing to launch its first robotaxis in Austin this June, with a small fleet of Model Ys powered by its camera-based Full Self-Driving (FSD) system. While Tesla aims for affordability and scale, Waymo and May are focused on safety-first deployments using sensor-rich systems, including lidar—a tech stack regulators have so far favored.
Beyond ride-hailing, the idea of personally owned self-driving cars is also gaining traction. Waymo and Toyota recently announced they’re exploring how to bring full autonomy to private vehicles, a move that could eventually bring robotaxi tech right into your garage.
With big names like Uber, Tesla, Waymo, and now May Mobility in the mix, the ride-hailing industry is evolving fast—and the road ahead looks increasingly driver-optional.

Read more